Why Boston Scientific's Big Dip Could Be a Bigger Opportunity

Boston Scientific branding over surgical device handling in sterile lab, reflecting medical device innovation and growth. Key Points Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance. Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition. A potential majo ...